Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors

CAR T cell therapy has shown great results in hematological malignancies but faces challenges in solid tumors.

• CAR T cells are genetically engineered to activate an immune response against cancer-specific antigens.
• Challenges in solid tumors include a lack of identifiable antigens and poor movement of CAR T cells within the tumor.
• The tumor microenvironment is often hostile, which may hinder the effectiveness of CAR T cell therapy.
• Ongoing research focuses on strategies to enhance the efficacy of CAR T cell therapy specifically for solid tumors.

AI simplified